Eisai Asks Court To Set Deadline For DEA Scheduling Of Its Epilepsy Drug Fycompa
Eisai says DEA’s scheduling delay – 10 months after FDA approval and seven months after HHS submitted a scheduling recommendation – is “unreasonable and egregious.” Court filing follows citizen petition to FDA.